Avantor ($AVTR) Guidance Revisions, CEO Transition, and Impairment Disclosure Case

The court has appointed the lead plaintiff to represent the class.

D. Delaware

Court

1:26-cv-00215

Case number

03/05/2024

Class period Start

10/28/2025

Class period End

12/29/2025

Lead Plaintiff motion deadline

$AVTR investors filed a claim against Avantor for allegedly misrepresenting its competitive strength and growth prospects while failing to disclose the extent of increasing market pressure, lost customer accounts, and margin deterioration.
After issuing three consecutive guidance cuts, announcing a CEO change, and disclosing a $785M impairment tied to competitive pressures, $AVTR declined 47% from March 4, 2024, to October 29, 2025.
$AVTR investors can join this case to be notified about potential recovery.
Case Details:

Between March 5, 2024, and October 28, 2025, Avantor executives stated the company was competitively well-positioned, emphasizing the strength of its Laboratory Solutions business and highlighting investments in digital capabilities and supply chain solutions. They projected low single-digit growth, and in February 2025, reassured investors that Avantor was "well-positioned for growth" in the year ahead. The company attributed performance to sustained momentum and advantages in biopharma and academic end markets.

On April 25, 2025, Avantor lowered its FY2025 guidance and announced that CEO Michael Stubblefield would step down. The company cited "increased competitive intensity" as a key headwind affecting volumes in Laboratory Solutions. 

Following the announcement, $AVTR dropped 16.5%, from $15.50 to $12.93. On August 1, 2025, Avantor again reduced guidance, reporting a 3% YoY sales decline in Lab Solutions and forecasting negative organic revenue growth. The stock fell another 15%, closing at $11.36.

Then on October 29, 2025, Avantor reported a larger-than-expected 5% decline in organic revenue, a net loss of $712 million, and a $785 million goodwill impairment, attributed in part to ongoing competitive pressure in the company’s lab distribution business. Executives acknowledged lost accounts and acknowledged that pricing pressure had materially impacted margins. The stock dropped another 23%, closing at $11.58.

Based on these events, $AVTR investors filed a claim against Avantor, alleging the company:
It misrepresented the strength of its competitive position and ability to retain key accounts.
It failed to disclose material headwinds affecting its core Laboratory Solutions business.
It issued guidance that lacked a reasonable basis amid known market deterioration.
Investors argue Avantor's disclosures did not accurately reflect the effects of rising competition and account attrition, leading to significant stock declines as revised guidance and impairment charges emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointed

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

10/29/2025

Filing date

10/30/2025

Lead Plaintiff Deadline

12/29/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.